N-terminal pro BNP and galectin-3 are prognostic biomarkers of acute heart failure in sub-Saharan Africa: lessons from the BAHEF trial

Mahmoud U Sani, Albertino Damasceno, Beth A Davison, Gad Cotter, Bongani M Mayosi, Christopher Edwards, Feriel Azibani, Tasneem Adam, Gulnaze Arif, Neusa Jessen, Karen Sliwa, Mahmoud U Sani, Albertino Damasceno, Beth A Davison, Gad Cotter, Bongani M Mayosi, Christopher Edwards, Feriel Azibani, Tasneem Adam, Gulnaze Arif, Neusa Jessen, Karen Sliwa

Abstract

Aims: The relationship between N-terminal pro-brain natriuretic peptide (NT-pro-BNP) and galectin-3 and outcomes has not been studied in African patients with acute heart failure (AHF). The current analysis sought to describe the association between plasma levels of NT-pro-BNP and galectin-3 and cardiovascular (CV) death or heart failure (HF) hospitalization, as well as their associations with symptoms and echocardiography markers of left and right ventricular remodelling among AHF patientsv in sub-Saharan Africa.

Methods and results: In a subset of 80 patients with complete data in a study assessing the effects of hydralazine and nitrates in patients with AHF (BAHEF trial; NCT01822808), NT-pro-BNP and galectin-3 analyses were performed, and the association with various characteristics and outcome measures assessed. The mean age of the patients for whom the aforementioned biomarkers were measured was 52.6 years, with 52.5% women. Galectin-3 at baseline predicted changes (Week 24 to baseline) in left ventricular ejection fraction, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, and tricuspid annular plane systolic excursion. Biomarkers and their changes were not associated with changes in 6 min walk test at 24 weeks. Baseline galectin-3 and change in NT-pro-BNP were associated with improvements in dyspnoea at 24 weeks. Nine patients had an HF readmission or died of CV causes through 24 weeks (11.6%). Both biomarkers at baseline predicted combined CV death or HF hospitalization through Week 24 (P-values = 0.0328 and 0.0001, respectively).

Conclusions: In a cohort of patients with AHF from sub-Saharan Africa, NT-pro-BNP and galectin-3 at baseline and their changes were associated with some changes in dyspnoea, echocardiographic remodelling, and CV death or HF hospitalization through Week 24. These tests have potential of being used for risk stratification of AHF patients in sub-Saharan Africa where resources are scarce.

Keywords: Acute heart failure; Africa; Galectin-3; NT-pro-BNP; Outcomes.

Conflict of interest statement

None of the authors in this manuscript has any conflict of interest as regards this manuscript.

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

References

    1. Mebazaa A, Gheorghiade M, Piña IL, Harjola VP, Hollenberg SM, Follath F, Rhodes A, Plaisance P, Roland E, Nieminen M, Komajda M, Parkhomenko A, Masip J, Zannad F, Filippatos G. Practical recommendations for prehospital and early in‐hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 2008; 36: S129–S139.
    1. Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, Sliwa K. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation 2008; 118: 2360–2367.
    1. Ojji D, Stewart S, Ajayi S, Manmak M, Sliwa K. A predominance of hypertensive heart failure in the Abuja Heart Study cohort of urban Nigerians: a prospective clinical registry of 1515 de novo cases. EurJHeart Fail 2013; 15: 835–842.
    1. Sliwa K, Stewart S. Heart failure in the developing world In Mann D., Michael Felker G., eds. Heart Failure: A Companion to Braunwald's Heart Disease. Philadelphia: Elsevier; 2016. p 410–419.
    1. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N‐terminal‐pro‐brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168–2174.
    1. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators . Rapid measurement of B‐type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161–167.
    1. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd‐Jones DM, Brown DF, Foran‐Melanson S, Sluss PM, Lee‐Lewandrowski E, Lewandrowski KB. The N‐terminal Pro‐BNP Investigation of Dyspnea in the Emergency department (PRIDE) study. Am J Cardiol 2005; 95: 948–954.
    1. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, Hlavin P, Maisel AS. B‐type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002; 39: 131–138.
    1. Aspromonte N, Valle R, Peacock WF, Vanderheyden M, Maisel A. Inpatient monitoring and prognostic importance of B‐type natriuretic peptide. Congest Heart Fail 2008; 14: 30–34.
    1. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin‐3 marks activated macrophages in failure‐prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121–3128.
    1. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin‐3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43: 60–68.
    1. Hrynchyshyn N, Jourdain P, Desnos M, Diebold B, Funck F. Galectin‐3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis 2013; 106: 541–546.
    1. Fermann GJ, Lindsell CJ, Storrow AB, Hart K, Sperling M, Roll S, Weintraub NL, Miller KF, Maron DJ, Naftilan AJ, McPherson JA, Sawyer DB, Christenson R, Collins SP. Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers 2012; 17: 706–713.
    1. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino‐terminal pro‐brain natriuretic peptide, galectin‐3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217–1224.
    1. Shah RV, Chen‐Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12: 826–832.
    1. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin‐3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL‐HF study. Clin Res Cardiol 2010; 99: 323–328.
    1. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D. Galectin‐3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012; 60: 1249–1256.
    1. Sliwa K, Damasceno A, Davison BA, Mayosi BM, Sani MU, Ogah O, Mondo C, Ojji D, Dzudie A, Kouam CK, Yonga G. Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with acute HEart Failure (BA‐HEF). Eur J Heart Fail 2016; 18: 1248–1258.
    1. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP, ADHERE Scientific Advisory Committee and Investigators . Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209–216.
    1. Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 2012; 172: 1386–1394.
    1. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049–2057.
    1. de Boer RA, van Veldhuisen DJ, de Filippii C. Plasma galectin‐3 is associated with near‐term rehospitalization in heart failure: a meta‐analysis. J Card Fail 2011; 17: S93.
    1. Ojji DB, Opie LH, Lecour S, Lacerda L, Adeyemi OM, Sliwa K. The proposed role of plasma NT pro‐brain natriuretic peptide in assessing cardiac remodelling in hypertensive African subjects. Cardiovasc J Afr 2014; 25: 233–238.
    1. Talwar S, Siebenhofer A, Williams B, Ng L. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Heart 2000; 83: 278–282.
    1. Stokes NR, Dietz BW, Liang JJ. Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea. Open Access Emerg Med 2016; 8: 35–45.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться